Evonik Industries AG Q3 2025 Earnings Recap

EVK.DE Q3 2025 November 4, 2025

Get alerts when EVK.DE reports next quarter

Evonik Industries experienced a challenging Q3 2025, prompting a reduction in full-year EBITDA guidance to EUR 1.9 billion, despite expectations for improved performance in Q4 due to sales recoveries in key segments.

Earnings Per Share Miss

$-0.23 vs $0.09 est.

-348.0% surprise

Revenue Beat

3391000000 vs 3371858820 est.

+0.6% surprise

Market Reaction

1-Day -0.91%

5-Day -3.56%

30-Day -10.34%

See EVK.DE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q3 EBITDA was notably weaker, primarily due to cautious customer behavior and ongoing market headwinds.
The company anticipates a recovery in Q4, driven by a year-end sales surge in the Health Care segment and increased capacity in Animal Nutrition.
Free cash flow showed positive progress, with approximately EUR 300 million generated in Q3, bolstering confidence in achieving cash conversion guidance of 30% to 40%.
Significant workforce reductions of over 740 employees were implemented, aimed at streamlining operations and supporting long-term strategy amidst a tough market landscape.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit EVK.DE on AllInvestView.